Further, efficacy data from a phase 1b clinical trial [NCT02263508] in 21 patients with advanced melanoma demonstrated that treatment with anti-PD-1 antibody (pembrolizumab) combined with T-VEC resulted to an increased tumor infiltration of IFN-γ+ CD8+ T-cells in patients with tumors with low level of immune cell infiltrates and negative IFN-γ+ signatures [8]. The gene discussed is CD8A; the disease is neoplasm.